STOCK TITAN
  1. Home
  2. News
  3. ABT

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated news page for Abbott Laboratories (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbott Laboratories's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbott Laboratories's position in the market.

News
Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
Rhea-AI Summary
Abbott reports Q3 2023 financial results with sales of $10.1 billion. Organic sales growth for underlying base business is 13.8%. Full-year 2023 EPS guidance range narrowed. Abbott acquires Bigfoot Biomedical and expands collaboration with mAbxience Holdings. Investments made during the pandemic drive broad-based growth. Abbott on track to deliver financial commitments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.71%
Tags
earnings
-
News
Abbott Hosts Conference Call for Third-Quarter Earnings
Rhea-AI Summary
Abbott to announce Q3 2023 financial results on Oct. 18 before market opens. Earnings conference call at 8am Central time. Webcast accessible through Abbott's Investor Relations website. Archived edition of the call available later.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
earnings
-
News
Abbott Shares Progress on Sustainability Performance, Including Company’s Priority of Innovating for Greater Health Access
Rhea-AI Summary
Abbott releases 2022 Global Sustainability Report, highlighting efforts to improve access and affordability of life-saving technologies. They introduced new health technologies at lower prices, reduced emissions, and achieved zero waste at 6 sites. Positive impact on stock price expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
News
Abbott Completes Acquisition of Bigfoot Biomedical
Rhea-AI Summary
Abbott completes acquisition of Bigfoot Biomedical, expanding presence in diabetes care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
acquisition
-
News
Abbott Declares 399th Consecutive Quarterly Dividend
Rhea-AI Summary
Abbott declares quarterly dividend of 51 cents per share, marking the 399th consecutive quarterly dividend since 1924. Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
dividends
-
News
Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets
Rhea-AI Summary
Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East, and Africa. First molecules expected to launch in 2025. Collaboration expands Abbott's medicines offering and provides access to affordable biosimilar medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
acquisition
News
Abbott and WeightWatchers Connected App Experience is Now Available for People Living with Diabetes
Rhea-AI Summary
Abbott and WeightWatchers announce a connected app to help people with diabetes understand how food and activity impact glucose levels. WeightWatchers members can now access glucose data from Abbott's FreeStyle Libre 2 system within the WW app. Maintaining a healthy weight is key to glucose control for people with Type 2 diabetes. Clinical data shows that healthy weight loss leads to a reduction in average glucose. The WW Diabetes-Tailored Plan has been proven to reduce hemoglobin A1c levels and decrease diabetes distress. New WW members can enjoy a free month of the WeightWatchers Diabetes-Tailored Plan and connect the WW app with the FreeStyle Libre 2 system. New FreeStyle Libre 2 users may be eligible for a free trial of the system. The FreeStyle Libre portfolio is the number one sensor-based glucose monitoring system in the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
-
News
Virus Hunt Zooms In To Focus on New Potential Pandemics
Rhea-AI Summary
Abbott Pandemic Defense Coalition contributes to virus studies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
-
News
One Size Does Not Fit All: The Future of Clinical Trials
Rhea-AI Summary
Abbott introduces three new programs to increase diversity in clinical trials and improve care among under-represented groups.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
clinical trial
News
Less Is More: Abbott’s Approach to Packaging Innovation
Rhea-AI Summary
Abbott is making swift progress towards its goal of addressing 50 million pounds of packaging by 2030, already reaching 59% of its packaging objective by the end of 2022. One example is the redesign of the BinaxNOW COVID-19 test kits, which reduced packaging size by 27% and weight by 58%, eliminating approximately 26.7 million pounds of packaging. Abbott's sustainability efforts in packaging also aim to improve efficiencies, reduce costs, and ensure market access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
none
Stock ABT logo
Abbott Laboratories

NYSE:ABT

ABT Rankings

#50 Ranked by Market Cap
#2392 Ranked by Stock Gains
#1396 Ranked by Dividends

ABT Stock Data

189.50B
1.72B
0.54%
77.02%
0.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
North Chicago

About ABT

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States.